Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Nano-X Imaging
NNOX
Nano-X Imaging
Rising Regulatory Hurdles Will Test Digital Imaging But Allow Revival
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.00
35.2% undervalued
intrinsic discount
24 Aug
US$3.89
1Y
-44.3%
7D
-8.7%
Loading
1Y
-44.3%
7D
-8.7%
Author's Valuation
US$6.0
35.2% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.0
35.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-103m
53m
2018
2020
2022
2024
2025
2026
2028
Revenue US$52.6m
Earnings US$2.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
50.48%
Healthcare Services revenue growth rate
0.26%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.34%
Calculation
US$2.83m
Earnings '28
x
224.50x
PE Ratio '28
=
US$636.16m
Market Cap '28
US$636.16m
Market Cap '28
/
83.39m
No. shares '28
=
US$7.63
Share Price '28
US$7.63
Share Price '28
Discounted to 2025 @ 8.34% p.a.
=
US$6.00
Fair Value '25
